← Back to Clinical Trials
Recruiting NCT06230341

NCT06230341 Patient Safety Incidents in Coordinated Primary Care Teams: a Multi-method Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06230341
Status Recruiting
Phase —
Sponsor Nantes University Hospital
Condition Adverse Event
Study Type INTERVENTIONAL
Enrollment 16 participants
Start Date 2024-12-10
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Health Services Research

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 16 participants in total. It began in 2024-12-10 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In France, improving the practice of health professionals working in coordinated primary care teams (health centres called Maisons de Santé Pluriprofessionnelles - MSPs) could be facilitated by a learning system consisting of (i) a risk management support programme and (ii) the provision of a comprehensive online system combining training, reporting and support for the analysis and management of patient safety incidents (PSIs). EVIDENS-Prim is a multi-method, multi-centre, prospective study. It aims to describe the PSIs that occur in MSPs, using an international classification system, and to describe the ways in which professionals have adopted a global approach to PSIs management, from PSI reporting to feedback.

Eligibility Criteria

Inclusion Criteria: * Characteristics of the MSPs included in the study: * Located in the Pays de la Loire region; * Having a contract with a health insurance (specifications and financing defined nationally) for at least 1 year; * Agreeing to take part in the project; * Having a quality representative or committing to appoint one when they join the project. Characteristics of professionals working in MSPs included: * All independent health professionals involved in the MSP: general practitioners and, depending on the MSP, nurses, pharmacists, podiatrists, physiotherapists, midwives, speech therapists, dentists, occupational therapists, psychomotor therapists, etc,) * All professionals involved in MSP outside the health sector: (coordinators, medical assistants, independent psychologists, etc.), * agree to take part in the project. Exclusion Criteria: Other group exercise modalities or other forms of coordinated exercise (other than MSP) do not have a quality representative on their team and will not be considered for inclusion. Characteristics of MSPs not included in the research: \- Where the members of the research team work. Characteristics of professionals working in MSPs included: \- Not included.

Contact & Investigator

Central Contact

Jean-Baptiste Amélineau, MD

✉ jean-baptiste.amelineau@univ-nantes.fr

📞 02 40 41 28 28

Frequently Asked Questions

Who can join the NCT06230341 clinical trial?

This trial is open to participants of all sexes, studying Adverse Event. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06230341 currently recruiting?

Yes, NCT06230341 is actively recruiting participants. Contact the research team at jean-baptiste.amelineau@univ-nantes.fr for enrollment information.

Where is the NCT06230341 trial being conducted?

This trial is being conducted at Nantes, France.

Who is sponsoring the NCT06230341 clinical trial?

NCT06230341 is sponsored by Nantes University Hospital. The trial plans to enroll 16 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology